期刊文献+

胎盘11β-HSD与病理妊娠的研究进展 被引量:3

Research advancement of placental 11β-HSD in Pathological Pregnancy
原文传递
导出
摘要 病理妊娠包括胎儿生长受限、妊娠期高血压疾病、妊娠期糖尿病等,是严重威胁母婴健康的疾病。对病理妊娠机制的深入研究,有助于我们在临床上更好的诊治。妊娠期间胎盘分泌的糖皮质激素代谢酶11β-羟基类固醇脱氢酶(11β-HSD,11β-hydroxysteroid dehydrogenase)的异常表达被认为与病理妊娠有关。11β-HSD分为11β-HSD1和11β-HSD2两种亚型。胎盘11β-HSD2为避免胎儿暴露于过量的糖皮质激素水平提供了屏障作用,保证胎儿正常生长发育。胎盘11β-HSD2表达和活性降低与胎儿生长受限有关。胎盘11β-HSD2的活性在妊娠期高血压疾病患者中是降低的,妊娠期高血压疾病也可导致胎盘11β-HSD2活性的进一步降低。胎盘11β-HSD1表达增加与胰岛素抵抗有关,可能参与妊娠期糖尿病的发病。针对胎盘11β-HSD的活性调节将是病理妊娠治疗的重要措施之一。 Pathological pregnancy including fetal growth restriction(FGR),preeclampsia,gestational diabetes mellitus(GDM),is a disease with serious threat to maternal and fetal health.An in-depth study on the pathogenesis of pathological pregnancy will help to achieve a better clinical diagnosis and treatment.During human pregnancy,placenta secretes a number of 11β-hydroxysteroid dehydrogenase(11β-HSD),which is thought to be relevant with pathological pregnancy.There are two subtypes of 11β-HSD:11β-HSD1 and 11β-HSD2.The placental 11β-HSD2 serves as a functional barrier to protect the fetus from excessive exposure to high levels of maternal cortisol to insure the normal fetal growth and development.The reduction of 11β-HSD2 expression and activity may correlate with FGR.11β-HSD2 activity is reduced in preeclampsia;vice versa,preeclampsia can further reduce 11β-HSD2 activity.Enhanced 11β-HSD1 activity correlates with insulin resistance and may contribute to GDM.Therefore,regulation of the placental 11β-HSD activity will be one of the important measures for the treatment of pathological pregnancy.
出处 《现代生物医学进展》 CAS 2010年第1期165-167,共3页 Progress in Modern Biomedicine
关键词 11Β-羟基类固醇脱氢酶 病理妊娠 胎儿生长受限 妊娠期高血压疾病 妊娠期糖尿病 11β-HSD Pathological pregnancy FGR Preeclampsia GDM
  • 相关文献

参考文献20

  • 1Bujalska J, Draper N, Michailidou Z, et al. Hexose-6-phosphate dehydrogenase confersoxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1 [J]. J Mol Endocrinol, 2005, 34(3): 675-684.
  • 2Seckl JR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action [J]. Curr Opin Pharmacol, 2004, 4(6): 597-602.
  • 3Manolis T, Lee YC, Temkin S, et al. NAD dependent hysteroid dehydrogenase activity in human endometrium and endometrium tumor [J]. Gynecol Obstet Invest, 2006, 62(2): 103-107.
  • 4Chan J, Rabbitt EH, Innes BA, et al. Glucocortieoid-induced apoptosis in human decidua: a novel role for l lbeta-hydroxysteroid dehydrogenase in late gestation [J]. J Endocrinol, 2007, 195(1): 7-15.
  • 5Kadereit B, Fustier P, Shojaati K, et al. Extracellular ATP determines 1 lbeta-hydroxysteroid dehydrogenase type 2 activity via purinergic receptors [J]. J Am Soc Nephrol, 2005, 16(12): 3507-3516.
  • 6Sato K, Chisaka H, Okamura K, et al. Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-beta dehydrogenase 2 in cultured human term placental trophoblasts [J]. Biol Reprod., 2008, 78(3): 514-520.
  • 7Homan A, Guan H, Hardy DB, et al.Hypoxia blocks 11beta-hydroxysteroid dehydrogenase type 2 induction in human trophoblast cells during differentiation by a time-dependent mechanism that involves both translation and transcription [J]. Placenta, 2006, 27(8): 832-840.
  • 8Van Beek JP, Guan H, Julan L, et al. Glucocorticoids stimulate the expression of 1 ll3-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells [J]. J CAin Endocrinol Metab, 2004, 89(11): 5614-5621.
  • 9Kossintseva I, Wong S, Johnstone E, et al. Proinflammatory cytokines inhibit human placental 1113-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways [J]. AM J Physiol Endocrinol Metab, 2006, 290(2): 282-288.
  • 10Murphy VE, Fittock R J, Zarzychi PK, et al. Metabolism of synthetic steroids by the human placenta [J]. Placenta, 2007, 28(1):39-46.

同被引文献24

  • 1李福琴,王雪清,王治英,艾丽敏.糖尿病孕妇胎盘微绒毛体视学研究[J].实用妇产科杂志,2004,20(4):217-218. 被引量:12
  • 2申彩霞,靳钰,张战红.妊娠期糖尿病胎盘微绒毛形态计量学改变与围产儿并发症关系的探讨[J].现代妇产科进展,2007,16(6):413-416. 被引量:13
  • 3Casey BM,Lucas MJ,Mcintire DD,et al.Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population.Obstet Gynecol,1997,90(6):869-873.
  • 4Desoye G,Shafrir E.Placental metaholism and its regulation in health and diabetes.Mol Aspects Med,1994,15(6):505-682.
  • 5Clarson C,Tevaarwerk GJ,Harding PG,et al.Placental weight in diabetic pregnancies.Placenta,1989,10(3):275-281.
  • 6Taricco E,Radaelli T,Nobile de Santis MS,et al.Foetal and placental weights in relation to maternal characteristics in gestational diabetes.Placenta,2003,24(4):343-347.
  • 7Calderon IM,Damasceno DC,Amorin RL,et al.Morphometric study of placental villi and vessels in women with mild hyperglycemia or gestational or overt diabetes.Diabetes Res Clin Pract,2007,78(1):65-71.
  • 8Pietryga M,Biczysko W,Wender-Ozegowska E,et al.Ultrastructural examination of the placenta in pregnancy complicated by diabetes mellitus[Article in Polish].Ginekol Pol,2004,75(2):111-118.
  • 9Jauniaux E,Burton GJ.Villous histomorphometry and placental bed biopsy investigation in type Ⅰ diabetic pregnancies.Placenta,2006,27(4-5):468-474.
  • 10Diamant YZ,Metzger BE,Freinkel N,et al.Placental lipid and glycogen content in human and experimental diabetes mellitus.Am J Obstet Gynecol,1982,144(1):5-11.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部